CY1112828T1 - Ενωσεις αναστολης της μιτωτικης διαδικασιας - Google Patents

Ενωσεις αναστολης της μιτωτικης διαδικασιας

Info

Publication number
CY1112828T1
CY1112828T1 CY20121100518T CY121100518T CY1112828T1 CY 1112828 T1 CY1112828 T1 CY 1112828T1 CY 20121100518 T CY20121100518 T CY 20121100518T CY 121100518 T CY121100518 T CY 121100518T CY 1112828 T1 CY1112828 T1 CY 1112828T1
Authority
CY
Cyprus
Prior art keywords
union
suspending
suspensions
procedures
compounds
Prior art date
Application number
CY20121100518T
Other languages
Greek (el)
English (en)
Inventor
Christopher F Claiborne
Todd B Sells
Stephen G Stroud
Original Assignee
Millennium Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112828(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals, Inc. filed Critical Millennium Pharmaceuticals, Inc.
Publication of CY1112828T1 publication Critical patent/CY1112828T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CY20121100518T 2006-11-16 2012-06-06 Ενωσεις αναστολης της μιτωτικης διαδικασιας CY1112828T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16
EP07867449A EP2086981B1 (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Publications (1)

Publication Number Publication Date
CY1112828T1 true CY1112828T1 (el) 2016-02-10

Family

ID=39315133

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100518T CY1112828T1 (el) 2006-11-16 2012-06-06 Ενωσεις αναστολης της μιτωτικης διαδικασιας

Country Status (34)

Country Link
US (7) US8026246B2 (enExample)
EP (4) EP2086981B1 (enExample)
JP (3) JP5102839B2 (enExample)
KR (2) KR101342014B1 (enExample)
CN (2) CN101547924B (enExample)
AR (1) AR064246A1 (enExample)
AT (1) ATE556076T1 (enExample)
AU (1) AU2007322046B2 (enExample)
BR (1) BRPI0718803B8 (enExample)
CA (1) CA2669680C (enExample)
CL (1) CL2007003244A1 (enExample)
CR (3) CR10782A (enExample)
CY (1) CY1112828T1 (enExample)
DK (2) DK2086981T3 (enExample)
EA (1) EA015779B1 (enExample)
ES (3) ES2384123T3 (enExample)
GE (1) GEP20125459B (enExample)
HR (2) HRP20120490T1 (enExample)
IL (1) IL198690A0 (enExample)
MA (1) MA30988B1 (enExample)
MX (3) MX348568B (enExample)
MY (1) MY153243A (enExample)
NO (1) NO343338B1 (enExample)
NZ (3) NZ611898A (enExample)
PH (1) PH12012502057B1 (enExample)
PL (2) PL2497772T3 (enExample)
PT (2) PT2086981E (enExample)
RS (2) RS52313B (enExample)
SG (2) SG10201503350TA (enExample)
SI (2) SI2086981T1 (enExample)
TW (1) TWI401255B (enExample)
UA (1) UA94129C2 (enExample)
WO (1) WO2008063525A1 (enExample)
ZA (1) ZA200903279B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52436B (sr) * 2004-05-14 2013-02-28 Millennium Pharmaceuticals Inc. Jedinjenja i postupci za inhibiciju napredovanja mitoze putem inhibicije aurora kinaze
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
WO2010065134A1 (en) * 2008-12-05 2010-06-10 Millennium Pharmaceuticals, Inc. 5, 7-dihydro- 6h-pyrimido [ 5, 4-d] [ 1 ] benzazepin-6-thiones as plk inhibitors
ES2468391T3 (es) * 2008-12-22 2014-06-16 Millennium Pharmaceuticals, Inc. Combinación de inhibidores de cinasas Aurora y anticuerpos anti-CD20
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
EP2536279A4 (en) * 2010-02-19 2013-07-24 Millennium Pharm Inc CRYSTALLINE FORMS OF SODIUM 4 - {[9-CHLORO-7- (2-FLUORO-6-METHOXYPHENYL) -5H-PYRIMIDO [5,4-D] [2] BENZAZEPHIN-2YL] AMINO} -2-METHOXYBENZOATE
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
US9085582B2 (en) * 2010-06-22 2015-07-21 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
UY34114A (es) 2011-06-03 2013-01-03 Millennium Pharm Inc Combinación de inhibidores de mek e inhibidores selectivos de la quiinasa aurora a
US20130303519A1 (en) * 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
EP2976086B1 (en) * 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
WO2015085289A1 (en) 2013-12-06 2015-06-11 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
CA2972076A1 (en) * 2014-12-23 2016-06-30 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
EP3324976A4 (en) 2015-07-21 2019-03-27 Millennium Pharmaceuticals, Inc. ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
CA2997769A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
CA2997784A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
JP6591036B2 (ja) 2016-02-26 2019-10-16 公益財団法人がん研究会 Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系
EA201892075A1 (ru) 2016-03-15 2019-04-30 Оризон Дженомикс, С.А. Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
JP2025511697A (ja) 2022-04-07 2025-04-16 イーライ リリー アンド カンパニー Ｋｒａｓ ｇ１２ｃ阻害剤を作製するための方法
CA3247183A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company TREATMENT METHOD INCLUDING KRAS G12C INHIBITORS AND AURORA A INHIBITORS
WO2024006424A1 (en) 2022-06-30 2024-01-04 Eli Lilly And Company Kras g12c inhibitor for treating cancer
WO2025075211A1 (en) 2023-10-03 2025-04-10 Takeda Pharmaceutical Company Limited Alisertib and paclitaxel for treating small cell lung cancer
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) * 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
NZ192803A (en) 1979-02-07 1984-08-24 Hoffmann La Roche Pyrimido-2-benzazepines and pharmaceutical compositions
US4481142A (en) * 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) * 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) * 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) * 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
WO1997032883A1 (en) 1996-03-08 1997-09-12 Zeneca Limited Azolobenzazepine derivatives as neurologically active agents
AU5330698A (en) 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
HUP0004020A3 (en) 1997-09-29 2002-12-28 Meiji Seika Kaisha Tricyclic triazolobenzazepine derivatives, process for producing the same, and their use as antiallergic agent
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
WO2000067754A1 (en) 1999-05-12 2000-11-16 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
DE60039782D1 (de) 1999-12-06 2008-09-18 Ajinomoto Kk Amidinophenylbrenztraubensäure-derivat
ES2375491T3 (es) 2000-12-21 2012-03-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol útiles como agentes inhibidores de las prote�?na-quinasas.
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
JP4364637B2 (ja) 2001-08-09 2009-11-18 アクテリオン ファーマシューティカルズ リミテッド 新規なベンゾ縮合へテロ環化合物
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
RS52436B (sr) * 2004-05-14 2013-02-28 Millennium Pharmaceuticals Inc. Jedinjenja i postupci za inhibiciju napredovanja mitoze putem inhibicije aurora kinaze
BRPI0517737A (pt) 2004-11-17 2008-10-21 Miikana Therapeutics Inc inibidores de quinase
EP1836188A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
JP5140600B2 (ja) 2005-12-23 2013-02-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー オーロラキナーゼのアザインドール阻害薬
EP2054413A2 (en) 2006-08-09 2009-05-06 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
GEP20125459B (en) 2012-03-26
NZ597252A (en) 2013-06-28
EP2497772B1 (en) 2014-10-29
EP2944639A1 (en) 2015-11-18
EP2497772A1 (en) 2012-09-12
NO343338B1 (no) 2019-02-04
SG176443A1 (en) 2011-12-29
EP2497773A1 (en) 2012-09-12
CN103483343B (zh) 2016-06-01
NO20091864L (no) 2009-06-15
HK1217699A1 (en) 2017-01-20
PL2497772T3 (pl) 2015-05-29
US20150166545A1 (en) 2015-06-18
ES2384123T3 (es) 2012-06-29
PT2497772E (pt) 2015-02-05
US20110312942A1 (en) 2011-12-22
KR101342014B1 (ko) 2013-12-19
US20210214361A1 (en) 2021-07-15
KR20090091173A (ko) 2009-08-26
TWI401255B (zh) 2013-07-11
EP2086981A1 (en) 2009-08-12
CR10782A (es) 2009-06-24
TW200829589A (en) 2008-07-16
EP2944639B1 (en) 2017-01-04
EP2086981B1 (en) 2012-05-02
PL2086981T3 (pl) 2012-09-28
EP2497773B1 (en) 2015-02-25
MX348568B (es) 2017-06-20
BRPI0718803B8 (pt) 2021-05-25
KR20110113210A (ko) 2011-10-14
CA2669680C (en) 2012-04-10
JP2012006965A (ja) 2012-01-12
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20
CL2007003244A1 (es) 2008-04-04
US20190031662A1 (en) 2019-01-31
US20080167292A1 (en) 2008-07-10
SG10201503350TA (en) 2015-06-29
SI2086981T1 (sl) 2012-12-31
BRPI0718803B1 (pt) 2020-11-17
JP2014055166A (ja) 2014-03-27
CN101547924B (zh) 2013-09-25
US11958855B2 (en) 2024-04-16
NZ611898A (en) 2015-01-30
HK1175778A1 (en) 2013-07-12
AU2007322046B2 (en) 2012-04-05
SI2497772T1 (sl) 2015-03-31
WO2008063525A1 (en) 2008-05-29
ES2537451T3 (es) 2015-06-08
CR20140544A (es) 2015-01-12
CR20140154A (es) 2014-07-23
KR101110458B1 (ko) 2012-03-13
DK2497772T3 (en) 2015-01-19
EA200970486A1 (ru) 2009-10-30
CN103483343A (zh) 2014-01-01
IL198690A0 (en) 2010-02-17
JP5452811B2 (ja) 2014-03-26
MX343391B (es) 2016-11-04
DK2086981T3 (da) 2012-08-06
ES2528793T3 (es) 2015-02-12
HRP20150047T1 (en) 2015-03-13
PH12012502057B1 (en) 2018-10-24
NZ577042A (en) 2012-03-30
US20240400567A1 (en) 2024-12-05
HK1134672A1 (en) 2010-05-07
HRP20120490T1 (hr) 2012-07-31
AR064246A1 (es) 2009-03-25
US9765076B2 (en) 2017-09-19
US20110312943A1 (en) 2011-12-22
MA30988B1 (fr) 2009-12-01
JP2010510215A (ja) 2010-04-02
BRPI0718803A2 (pt) 2013-12-03
RS53788B1 (sr) 2015-06-30
AU2007322046A1 (en) 2008-05-29
MY153243A (en) 2015-01-29
ATE556076T1 (de) 2012-05-15
US9988384B2 (en) 2018-06-05
CA2669680A1 (en) 2008-05-29
UA94129C2 (ru) 2011-04-11
HK1175777A1 (en) 2013-07-12
ZA200903279B (en) 2010-07-28
PH12012502057A1 (en) 2015-09-14
EA015779B1 (ru) 2011-12-30
US10836766B2 (en) 2020-11-17
CN101547924A (zh) 2009-09-30
JP5102839B2 (ja) 2012-12-19
RS52313B (sr) 2012-12-31
US8026246B2 (en) 2011-09-27

Similar Documents

Publication Publication Date Title
CY1112828T1 (el) Ενωσεις αναστολης της μιτωτικης διαδικασιας
CY1113192T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου μεσω αναστολης της κινασης aurora
EA200970156A1 (ru) Пиридизиноновые производные
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
NO20073790L (no) Kjemiske forbindelser
NO20073788L (no) Kjemiske forbindelser
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
EA201100030A1 (ru) Пиразольные соединения 436
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
CY1113386T1 (el) Αναστολεις πρωτεασωματος
CY1111197T1 (el) Tριαζολες χρησιμες ως αναστολεις πρετεϊνικων κινασων
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
EA200970856A1 (ru) Ингибиторы пути хеджхога
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
CY1113409T1 (el) Αναστολεις ακτ και ρ70 s6 κινασης
EA200900135A1 (ru) Производные пиразола в качестве ингибиторов цитохрома р450
CY1118012T1 (el) Συνθεσεις αναστολεων κινασης και η χρηση αυτων για την αγωγη καρκινου και αλλων νοσηματων σχετικων προς τις κινασες
EA201170832A1 (ru) Пуриновые соединения
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
EA200601391A1 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств